Abstract
Background and Hypothesis Around 30% of people with schizophrenia are refractory to antipsychotic treatment (treatment-resistant schizophrenia; TRS). While abnormal structural neuroimaging findings, in particular volume and thickness reductions, are often observed in schizophrenia, it is anticipated that biomarkers of neuronal injury like neurofilament light chain protein (NfL) can improve our understanding of the pathological basis underlying schizophrenia. The current study aimed to determine whether people with TRS demonstrate different associations between plasma NfL levels and regional cortical thickness reductions compared with controls.
Study Design Measurements of plasma NfL and cortical thickness were obtained from 39 individuals with TRS, and 43 healthy controls. T1-weighted magnetic resonance imaging sequences were obtained and processed via FreeSurfer. General linear mixed models adjusting for age and weight were estimated to determine whether the interaction between diagnostic group and plasma NfL level predicted lower cortical thickness across frontotemporal structures and the insula.
Study Results. Significant (false discovery rate corrected) cortical thinning of the left (p = 0.001, η2p = 0.104) and right (p < 0.001, η2 = 0.167) insula was associated with higher levels of plasma NfL in TRS, but not in healthy controls.
Conclusions. The association between regional thickness reduction of the insula bilaterally and plasma NfL may reflect a neurodegenerative process during the course of TRS. The findings of the present study suggest that some level of cortical degeneration localised to the bilateral insula may exist in people with TRS, which is not observed in the normal population.
Competing Interest Statement
The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. The remaining authors have nothing to disclose.
Funding Statement
National Health and Medical Research Councile (NHMRC) Ideas Grant (1185180). The TRS biobank was established by IE, CP, CB as part of a major Australian Department of Industry Co-operative Research Centre (CRC) grant - https://researchdata.ands.org.au/treatment-resistant-schizophrenia-biobank/1325206. The role of these funding sources was to support research study staff and biosample analyses.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Cooperative Research Centre (CRC) Psychosis Study protocol and this project were approved by the Melbourne Health Human Research Ethics Committee (ethics IDs 2012.069 and 2020.142, respectively).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
bjcilia{at}student.unimelb.edu.au, deratne{at}unimelb.edu.au, cassandra.wannan{at}orygen.org.au, charles.malpas{at}unimelb.edu.au, shorena.janelidze{at}med.lu.se, oskar.hansson{at}med.lu.se, ieverall{at}gmail.com, chad.bousman{at}ucalgary.ca, Naveen.Thomas{at}wh.org.au, Alexander.santillo{at}med.lu.se, dennisv{at}unimelb.edu.au, cpant{at}unimelb.edu.au
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos